Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.
The Session 9 of the Modern Vaccine Adjuvant/Formulation meeting pointed out the permanent need for vaccine improvement and for adjuvant development. Indeed, the increasing use of recombinant subunit vaccines for both parenteral and mucosal vaccination necessitates the development of improved adjuvants. This session dealt with strategies for the development of new vaccine adjuvants with respect to the availability of new molecules targeting specifically the receptors of the systemic or mucosal immune system.
Discovery Department; Sanofi Pasteur; Campus Mérieux; Marcy l'Etoile, France.
François
F
Dalençon
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000302:isolation & purification*; D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends*; D003165:Complement System Proteins / Q000276:immunology; D055808:Drug Discovery / Q000379:methods* / Q000639:trends*; D006801:Humans; D011971:Receptors, Immunologic / Q000819:agonists; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000276:immunology; D013557:Switzerland; D014612:Vaccines / Q000737:chemistry / Q000276:immunology* / Q000302:isolation & purification*
D000276:Adjuvants, Immunologic; D011971:Receptors, Immunologic; D022261:Respiratory Syncytial Virus Vaccines; D014612:Vaccines; D003165:Complement System Proteins
T-cell response; adjuvants; formulation; mucosal immunity